Novel bioactive peptides to revolutionize anti-inflammatory steroid-sparing strategies.

Immunomodulatory peptides are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, ophtalmology and respiratory care, as standalone drugs or as part of steroid-sparing therapeutic approaches.

EVO Peptides

EVORA Biosciences develops EVO peptides. Novel, patent-protected peptides which exhibit strong anti-inflammatory potency alongside a very favorable profile for development as an immunomodulatory drug.

  • Selective anti-inflammatory effect
  • Stable
  • Non-toxic
  • Amenable to multiple formulation options

Management

Hadrien Lanvin, MSc
CEO
Anna Kostrzak, PhD
Head of R&D

Directors

Hadrien Lanvin, MSc
CEO EVORA
Bruno Toque, PhD
Ex-Founder, CEO Exonhit Therapeutics
Philippe Rousseau, MSc
CEO Xenothera
Rémi Gloeckler, PhD
Ex-VP Industrial Partnerships, Ex-VP Industrial Operations
Transgene

Partners Network

EVORA Biosciences is supported by

contact@evorabio.com

© EVORA Biosciences 2024